Calidi Biotherapeutics Files S-1, Signaling Potential Capital Raise
Ticker: CLDWW · Form: S-1 · Filed: Jul 3, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | S-1 |
| Filed Date | Jul 3, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Biotechnology, S-1 Filing, Capital Raise, Oncolytic Viruses, Clinical Trials, Biopharma, SEC Filing
Related Tickers: CLDWW
TL;DR
Calidi's S-1 is a red flag for immediate dilution, but a green light for long-term biotech funding if they execute.
AI Summary
Calidi Biotherapeutics, Inc. (CLDWW) filed an S-1 on July 3, 2025, indicating a registration statement for securities, likely related to a public offering or resale. The company, formerly First Light Acquisition Group, Inc., operates in the biological products sector. Financial data for the quarter ended March 31, 2025, and the fiscal year ended December 31, 2024, shows ongoing operational activities. The filing details changes in common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings for both parent and noncontrolling interests. Specific dollar amounts for revenue and net income are not explicitly detailed in the provided excerpt, but the filing covers financial positions as of March 31, 2025, and December 31, 2024, and operational periods for the three months ended March 31, 2025, and 2024, and the years ended December 31, 2024, and 2023. The S-1 also includes information on related and non-related party transactions, suggesting a complex financial structure. The strategic outlook is focused on advancing its biological products, as evidenced by its SIC code 2836.
Why It Matters
This S-1 filing by Calidi Biotherapeutics (CLDWW) is crucial for investors as it signals a potential capital raise or the registration of shares for resale, which could dilute existing shareholder value or provide necessary funding for its biological product development. For employees, a successful capital raise could secure job stability and fund further research in the competitive biotech landscape. Customers could benefit from accelerated development of new biological products, while the broader market will watch how Calidi navigates its financial strategy in the highly capital-intensive pharmaceutical sector, where competition from established players is fierce.
Risk Assessment
Risk Level: medium — The risk level is medium because while the S-1 indicates a potential capital infusion, the lack of specific revenue and net income figures in the provided excerpt makes it difficult to assess the company's current financial health. The filing's focus on registering securities suggests a need for capital, which could lead to dilution for existing shareholders, as seen in the changes to 'Additional Paid-In CapitalMember' and 'CommonStockMember' across periods.
Analyst Insight
Investors should closely monitor the specifics of the offering once available to understand the extent of potential dilution and the intended use of proceeds. Evaluate Calidi's pipeline and clinical trial progress, as the success of its biological products will be critical to long-term value creation.
Key Numbers
- 2025-07-03 — Filing Date (Date the S-1 was filed with the SEC)
- 0001855485 — Central Index Key (CIK) (Unique identifier for Calidi Biotherapeutics, Inc.)
- 2836 — SIC Code (Standard Industrial Classification for Biological Products (No Diagnostic Substances))
- 2025-03-31 — Latest Quarter End (End date for the most recent financial period reported in the S-1)
- 2024-12-31 — Latest Fiscal Year End (End date for the most recent fiscal year reported in the S-1)
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Filer of the S-1 registration statement
- First Light Acquisition Group, Inc. (company) — Former name of Calidi Biotherapeutics, Inc.
- SEC (regulator) — Recipient of the S-1 filing
- 03 Life Sciences (company) — Organization name associated with the filer
- San Diego, CA (location) — Business address of Calidi Biotherapeutics, Inc.
FAQ
What is the primary purpose of Calidi Biotherapeutics' S-1 filing?
The S-1 filing by Calidi Biotherapeutics (CLDWW) on July 3, 2025, is a registration statement for securities, typically indicating a potential public offering or the registration of shares for resale, aimed at raising capital or allowing existing shareholders to sell shares.
What financial periods are covered in Calidi Biotherapeutics' S-1?
The S-1 covers financial positions as of March 31, 2025, and December 31, 2024, and operational periods for the three months ended March 31, 2025, and 2024, as well as the fiscal years ended December 31, 2024, and 2023.
What industry does Calidi Biotherapeutics operate in?
Calidi Biotherapeutics operates in the 'Biological Products (No Diagnostic Substances)' industry, as indicated by its Standard Industrial Classification (SIC) code 2836.
What was Calidi Biotherapeutics' previous company name?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc. before its name change on April 6, 2021.
Where is Calidi Biotherapeutics' business located?
Calidi Biotherapeutics' business address is 4475 Executive Drive, Suite 200, San Diego, CA 92121.
What are the potential risks for investors following Calidi Biotherapeutics' S-1 filing?
A key risk for investors is potential dilution of their holdings if the S-1 leads to a new public offering of shares. The lack of detailed revenue and net income figures in the provided excerpt also presents a risk in assessing the company's immediate financial viability.
How does the S-1 filing impact Calidi Biotherapeutics' capital structure?
The S-1 filing details changes in 'CommonStockMember' and 'AdditionalPaidInCapitalMember' for both parent and noncontrolling interests, indicating shifts in the company's equity and capital structure, likely in preparation for or as a result of capital-raising activities.
What is the significance of the 'Related Party Member' disclosures in the S-1?
The 'Related Party Member' disclosures in the S-1 highlight transactions or relationships with parties that could influence the company's financial statements or operations, which is important for investors to understand potential conflicts of interest or non-arm's length dealings.
What should investors look for next from Calidi Biotherapeutics after this S-1?
Investors should look for the definitive terms of any offering, including pricing and the number of shares, as well as more detailed financial statements and updates on their biological product pipeline and clinical trial progress to gauge future prospects.
What is Calidi Biotherapeutics' fiscal year end?
Calidi Biotherapeutics' fiscal year ends on December 31, as stated in the filing data.
Industry Context
Calidi Biotherapeutics operates within the biological products sector (SIC 2836), a highly competitive and innovation-driven industry. Companies in this space focus on developing novel therapeutics, often involving complex research and development cycles, significant capital investment, and stringent regulatory oversight from bodies like the FDA.
Regulatory Implications
As a biological products company, Calidi Biotherapeutics is subject to extensive regulatory scrutiny, particularly concerning clinical trials, manufacturing processes, and marketing approvals. The S-1 filing implies potential new offerings or resales, which must comply with SEC regulations, while ongoing operations necessitate adherence to FDA guidelines for drug development and safety.
What Investors Should Do
- Review the full S-1 filing for detailed financial statements and disclosures.
- Analyze the company's cash burn rate and funding runway.
- Investigate the nature of the securities being registered.
Key Dates
- 2025-07-03: S-1 Filing — Indicates a registration statement for securities, likely for an offering or resale, providing updated financial and business information.
- 2021-04-06: Name Change — Company formerly known as First Light Acquisition Group, Inc. changed its name to Calidi Biotherapeutics, Inc., marking a strategic shift or rebranding.
- 2025-03-31: Latest Quarter End — Represents the most recent financial position and operational period reported in the S-1 filing.
- 2024-12-31: Latest Fiscal Year End — Marks the end of the most recent full fiscal year for which financial data is presented in the S-1.
Glossary
- S-1 Filing
- A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies intending to offer securities to the public. (This filing provides comprehensive details about Calidi Biotherapeutics' business, financial condition, and the securities being offered.)
- SIC Code 2836
- Standard Industrial Classification code for Biological Products (No Diagnostic Substances). (Indicates Calidi Biotherapeutics operates in the sector focused on developing and manufacturing biological products, excluding diagnostic substances.)
- Additional Paid-In Capital
- The amount of capital contributed by investors in excess of the par value of the stock. (Reflects capital raised from stock issuance beyond the stated par value, a key component of the company's equity structure.)
- Accumulated Other Comprehensive Income
- A component of equity that includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension adjustments. (Provides insight into specific non-operating gains and losses that affect the company's overall equity but are not included in net income.)
- Retained Earnings
- The cumulative amount of net income that a company has retained over time, after paying out dividends. (Indicates the company's historical profitability and its policy on reinvesting earnings back into the business.)
- Noncontrolling Interest
- The portion of equity in a subsidiary that is not attributable to the parent company. (Relevant for companies with subsidiaries, showing the ownership stake held by external parties in consolidated financial statements.)
Year-Over-Year Comparison
As this is the initial deep structural analysis based on the provided excerpt of the S-1 filing dated July 3, 2025, a direct comparison to a previous filing is not possible. However, the S-1 itself indicates a history, including a name change from First Light Acquisition Group, Inc. in 2021, suggesting evolution in the company's strategy or focus. The filing covers financial data up to March 31, 2025, and December 31, 2024, providing a snapshot of its current financial standing and operational periods compared to prior years (2024 vs. 2023, and Q1 2025 vs. Q1 2024), though specific comparative metrics are not detailed in the excerpt.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on July 3, 2025 regarding Calidi Biotherapeutics, Inc. (CLDWW).